Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 930

1.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators.

N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.

PMID:
26196665
2.

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.

Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Yin MT.

Ann Intern Med. 2015 Jun 16;162(12):815-24. doi: 10.7326/M14-1409.

PMID:
26075752
3.

Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.

Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):168-77. doi: 10.1097/QAI.0000000000000557.

PMID:
26009829
4.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G, Hudey S, Goodenow MM, Sleasman JW; Adolescent Trials Network for HIVAIDS Interventions.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):52-60. doi: 10.1097/QAI.0000000000000549.

PMID:
25942459
5.

Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study.

Kintu A, Hankinson SE, Balasubramanian R, Ertel K, Tumwesigye E, Bangsberg DR, Haberer JE; Partners Ancillary Adherence Study Team.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):36-43. doi: 10.1097/QAI.0000000000000538.

PMID:
25942457
6.

Pre-exposure prophylaxis works--it's time to deliver.

Beyrer C, Bekker LG, Pozniak A, Barré-Sinoussi F.

Lancet. 2015 Apr 18;385(9977):1482-4. doi: 10.1016/S0140-6736(15)60724-3. No abstract available.

PMID:
25933264
7.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team.

Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.

PMID:
25890673
8.

Tenofovir alafenamide for HIV infection: is less more?

Wyatt C, Baeten JM.

Lancet. 2015 Jun 27;385(9987):2559-60. doi: 10.1016/S0140-6736(15)60725-5. Epub 2015 Apr 15. No abstract available.

PMID:
25890672
9.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567.

PMID:
25831464
10.

Painless penile papule.

Marszalek RM, Bae-Harboe YS, Mahalingam M, Masterpol K.

J Fam Pract. 2015 Mar;64(3):185-8. No abstract available.

PMID:
25789346
11.

Antiretroviral chemoprophylaxis: new successes and questions.

Mayer KH.

Lancet. 2015 Jun 6;385(9984):2236-7. doi: 10.1016/S0140-6736(15)60494-9. Epub 2015 Mar 11. No abstract available.

PMID:
25769358
12.

Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Castillo-Mancilla JR, Meditz A, Wilson C, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):495-501. doi: 10.1097/QAI.0000000000000529.

PMID:
25763783
13.

The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.

Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, Skhosana J, Odhiambo J, Van Damme L.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578-84. doi: 10.1097/QAI.0000000000000525.

PMID:
25761233
14.

Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques.

Santangelo PJ, Rogers KA, Zurla C, Blanchard EL, Gumber S, Strait K, Connor-Stroud F, Schuster DM, Amancha PK, Hong JJ, Byrareddy SN, Hoxie JA, Vidakovic B, Ansari AA, Hunter E, Villinger F.

Nat Methods. 2015 May;12(5):427-32. doi: 10.1038/nmeth.3320. Epub 2015 Mar 9.

PMID:
25751144
15.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group.

Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.

PMID:
25701561
16.

Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.

Greig SL, Deeks ED.

Drugs. 2015 Apr;75(5):503-14. doi: 10.1007/s40265-015-0361-6. Review. Erratum in: Drugs. 2015 Apr;75(5):561.

PMID:
25698454
17.

Preventing HIV in women--still trying to find their VOICE.

Saag MS.

N Engl J Med. 2015 Feb 5;372(6):564-6. doi: 10.1056/NEJMe1415750. No abstract available.

18.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM; VOICE Study Team.

N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.

19.

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.

Rodriguez-Torres M, Gaggar A, Shen G, Kirby B, Svarovskaia E, Brainard D, Symonds WT, McHutchison JG, Gonzalez M, Rodriguez-Orengo J.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):543-9. doi: 10.1097/QAI.0000000000000516.

PMID:
25622055
20.

Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.

Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D; FEM-PrEP Study Group.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):196-203. doi: 10.1097/QAI.0000000000000413.

PMID:
25590272
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk